These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 28882471)

  • 41. Comparing cognitive functions in medication adherent and non-adherent patients with schizophrenia.
    El-Missiry A; Elbatrawy A; El Missiry M; Moneim DA; Ali R; Essawy H
    J Psychiatr Res; 2015 Nov; 70():106-12. PubMed ID: 26424429
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a Positive and Negative Syndrome Scale, five-factor analysis).
    Miyaoka T; Furuya M; Horiguchi J; Wake R; Hashioka S; Tohyama M; Mori N; Minabe Y; Iyo M; Ueno S; Ezoe S; Murotani K; Hoshino S; Seno H
    Psychopharmacology (Berl); 2015 Jan; 232(1):155-64. PubMed ID: 24923986
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia.
    Tuğal O; Yazici KM; Anil Yağcioğlu AE; Göğüş A
    Int J Neuropsychopharmacol; 2004 Jun; 7(2):117-23. PubMed ID: 14741060
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sodium nitroprusside treatment for psychotic symptoms and cognitive deficits of schizophrenia: A randomized, double-blind, placebo-controlled trial.
    Wang X; Zhao J; Hu Y; Jiao Z; Lu Y; Ding M; Kou Y; Li B; Meng F; Zhao H; Li H; Li W; Yang Y; Lv L
    Psychiatry Res; 2018 Nov; 269():271-277. PubMed ID: 30170285
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
    Chen ZH; Wang GH; Wang XP; Chen RY; Wang HL; Yang MH; Huo YX; Mei HB
    Hum Psychopharmacol; 2008 Aug; 23(6):465-70. PubMed ID: 18536066
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effect of olanzapine treatment on cognitive functions in patients with schizophrenia].
    Radziwiłłowicz P; Radziwiłłowicz W; Lis J
    Psychiatr Pol; 2002; 36(6):967-87. PubMed ID: 12725025
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial.
    Mowla A; Mosavinasab M; Pani A
    J Clin Psychopharmacol; 2007 Feb; 27(1):67-70. PubMed ID: 17224716
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
    Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
    J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Elevated angiotensin-converting enzyme (kininase II) in the cerebrospinal fluid of neuroleptic-treated schizophrenic patients.
    Wahlbeck K; Rimón R; Fyhrquist F
    Schizophr Res; 1993 Mar; 9(1):77-82. PubMed ID: 8096392
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial.
    Roffman JL; Petruzzi LJ; Tanner AS; Brown HE; Eryilmaz H; Ho NF; Giegold M; Silverstein NJ; Bottiglieri T; Manoach DS; Smoller JW; Henderson DC; Goff DC
    Mol Psychiatry; 2018 Feb; 23(2):316-322. PubMed ID: 28289280
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clozapine alone versus clozapine and risperidone with refractory schizophrenia.
    Honer WG; Thornton AE; Chen EY; Chan RC; Wong JO; Bergmann A; Falkai P; Pomarol-Clotet E; McKenna PJ; Stip E; Williams R; MacEwan GW; Wasan K; Procyshyn R;
    N Engl J Med; 2006 Feb; 354(5):472-82. PubMed ID: 16452559
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study.
    Takiguchi K; Uezato A; Itasaka M; Atsuta H; Narushima K; Yamamoto N; Kurumaji A; Tomita M; Oshima K; Shoda K; Tamaru M; Nakataki M; Okazaki M; Ishiwata S; Ishiwata Y; Yasuhara M; Arima K; Ohmori T; Nishikawa T
    BMC Psychiatry; 2017 Jul; 17(1):249. PubMed ID: 28701225
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients.
    Good KP; Rabinowitz J; Whitehorn D; Harvey PD; DeSmedt G; Kopala LC
    Schizophr Res; 2004 May; 68(1):11-9. PubMed ID: 15037335
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adjunctive Memantine Treatment of Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Study.
    Hassanpour F; Zarghami M; Mouodi S; Moosazadeh M; Barzegar F; Bagheri M; Hendouei N
    J Clin Psychopharmacol; 2019; 39(6):634-638. PubMed ID: 31688396
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
    Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
    J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
    Bugarski-Kirola D; Iwata N; Sameljak S; Reid C; Blaettler T; Millar L; Marques TR; Garibaldi G; Kapur S
    Lancet Psychiatry; 2016 Dec; 3(12):1115-1128. PubMed ID: 27816567
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.
    Chang WC; Ming Hui CL; Yan Wong GH; Wa Chan SK; Ming Lee EH; Hai Chen EY
    J Clin Psychiatry; 2013 Nov; 74(11):e1046-53. PubMed ID: 24330905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.